Devices for Safety and Independence with Daily Activities
Sarah Dahlhauser, OTR/L, OTD, and Sarah Boyd, PT, DPT, discuss strategies to maximize your independence and safety with simple strategies and equipment to facilitate your function and enhance quality of life.
Join us on September 23, at 2:30 p.m. ET, to hear Lars Oddsson, PhD, and Laura Jacobs, PT, DPT, give an overview on balance, challenges that may face patients with peripheral neuropathy as they manage the all-important issues related to balance, and suggestions for managing those challenges.
Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
In a randomized clinical trial performed by Dr. Richard Barohn including 402 patients with cryptogenic sensory polyneuropathy, four drugs were tested for performance in pain relief. Overall, the findings showed that nortriptyline and duloxetine performed better than pregabalin and mexiletine when efficacy and tolerability were both considered.
The Foundation for Peripheral Neuropathy was happy to be a champion of this trial and pleased that Dr. Barohn’s study is now published in JAMA Neurology.
New Hampshire Law Protects Patient Access to Rx Opioids
Patient advocates around the country are looking with keen interest at a new law in New Hampshire that stipulates chronic pain patients should have access to opioid medication if it improves their physical function and quality of life.
Quell® is to be Evaluated for Chemotherapy-Induced PN
NeuroMetrix, Inc. recently announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial of the efficacy of transcutaneous electrical nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN).
RxFunction Awarded Defense Contract for R&D Project
“Although we continue our focus on the Walkasins neuroprosthesis technology for individuals with sensory peripheral neuropathy who have gait and balance problems, this Department of Defense contract award will allow us to expand our technology platform towards use in enhanced rehabilitation for individuals with lower limb trauma and/or loss. Furthermore, the project involves close collaboration with a major prosthesis company, which could further leverage strategic opportunities for us.” -Lars Oddsson
Lars Oddsson, PhD, is a scientist and professor. He is also Co-Founder and Chief Technology Officer of RxFunction, Inc., and co-inventor of Walkasins, an RxFunction product to help patients with challenges with balance due to peripheral nerve damage.
If you have had COVID-19 or been impacted by the COVID-19 pandemic, please answer our survey to give your input and your insights. By answering our survey, FPN is offering you an opportunity to bring your first-hand experience to doctors and scientists- as well as help us focus our programming to help you.
This survey is intended only for PN patients who have had COVID-19.
Devices for Safety and Independence with Daily Activities
Webinar: A Sense of Balance
Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)
New Hampshire Law Protects Patient Access to Rx Opioids
Quell® is to be Evaluated for Chemotherapy-Induced PN
RxFunction Awarded Defense Contract for R&D Project
Survey: COVID-19 and PN.png)
